Cited by 801Protein Kinase Regulation and GTPase SignalingProtein Tyrosine PhosphatasesMelanoma and MAPK Pathways

The DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.

Dragging Ras Back in the Ring

Open access

Stephen, Andrew G., Esposito, Dominic, Bagni, Rachel K., McCormick, Frank·2014·Cancer Cell

DOI 10.1016/j.ccr.2014.02.017

Open this paper in CoChat — free account Open PDF

Abstract

Ras proteins play a major role in human cancers but have not yielded to therapeutic attack. Ras-driven cancers are among the most difficult to treat and often excluded from therapies. The Ras proteins have been termed "undruggable," based on failures from an era in which understanding of signaling transduction, feedback loops, redundancy, tumor heterogeneity, and Ras' oncogenic role was poor. Structures of Ras oncoproteins bound to their effectors or regulators are unsolved, and it is unknown precisely how Ras proteins activate their downstream targets. These knowledge gaps have impaired development of therapeutic strategies. A better understanding of Ras biology and biochemistry, coupled with new ways of targeting undruggable proteins, is likely to lead to new ways of defeating Ras-driven cancers.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2014.02.017

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
ras GENES
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D. B., Tolcher, A. W., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,541
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Self-citation
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou‐Alfa, G. K., Schwartz, L. H., Ricci, S., Amadori, D., Santoro, A., Figer, A., Grève, J. D., Douillard, J., Lathia, C. D., Schwartz, B. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195

Flagged first, then by citations

Show all 87 references

1 of the 87 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 801

Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth
Tang, R., Shuldiner, E. G., Kelly, M. R., Murray, C. W., Hebert, J. D., Andrejka, L., Tsai, M. K., Hughes, N. W., Parker, M. I., Cai, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01049-w · Cited by 38
Synergy of WEE1 and mTOR Inhibition in Mutant KRAS -Driven Lung Cancers
Hai, J., Liu, S., Bufe, L. E., Do, K. T., Chen, T., Wang, X., Ng, C., Li, S., Tsao, M., Shapiro, G. I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1098 · Cited by 36
pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins
Prakash, P., Sayyed–Ahmad, A., & Gorfe, A. A. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004469 · Cited by 36
Long-Chain n-3 Fatty Acids Attenuate Oncogenic KRas-Driven Proliferation by Altering Plasma Membrane Nanoscale Proteolipid Composition
Fuentes, N. R., Mlih, M., Barhoumi, R., Fan, Y., Hardin, P. E., Steele, T. J., Behmer, S. T., Prior, I. A., Karpac, J., & Chapkin, R. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0324 · Cited by 34
H-Ras activation and fibroblast-induced TGF-β signaling promote laminin-332 accumulation and invasion in cutaneous squamous cell carcinoma
Siljamäki, E., Rappu, P., Riihilä, P., Nissinen, L. M., Kähäri, V., & Heino, J. (2019) · Matrix Biology · doi:10.1016/j.matbio.2019.09.001 · Cited by 35
Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data
Karatrasoglou, E. A., Chatziandreou, I., Sakellariou, S., Stamopoulos, K., Kavantzas, N., Lazaris, A. C., Korkolopoulou, P. A., & Saetta, A. A. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02756-1 · Cited by 34
Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine
Qian, L. M., Chen, K., Wang, C., Chen, Z., Meng, Z., & Wang, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2604 · Cited by 34
Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
Osaka, N., Hirota, Y., Ito, D., Ikeda, Y., Kamata, R., Fujii, Y., Chirasani, V. R., Campbell, S. L., Takeuchi, K., Senda, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707439 · Cited by 35
Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210739 · Cited by 33
Cracking the Codes behind Cancer Cells’ Immune Evasion
Mundhara, N., & Sadhukhan, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168899 · Cited by 37
Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface
Ye, X., Chan, K. C., Waters, A. M., Bess, M., Harned, A., Wei, B., Lončarek, J., Luke, B. T., Orsburn, B. C., Hollinger, B. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13566 · Cited by 33
Self-citation
Thyroid transcription factor‐1‐regulated micro RNA ‐532‐5p targets KRAS and MKL 2 oncogenes and induces apoptosis in lung adenocarcinoma cells
Griesing, S., Kajino, T., Tai, M.-C., Liu, Z., Nakatochi, M., Shimada, Y., Suzuki, M., & Takahashi, T. (2017) · Cancer Science · doi:10.1111/cas.13271 · Cited by 34
Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene
Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 33
Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues
Dacoba, T. G., Anthiya, S., Berrecoso, G., Fernández‐Mariño, I., Fernández‐Varela, C., Crecente‐Campo, J., Teijeiro‐Osorio, D., Torres, F., & Alonso, M. J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009860 · Cited by 34
A Sos proteomimetic as a pan-Ras inhibitor
Hong, S. H., Yoo, D. Y., Conway, L. P., Richards-Corke, K. C., Parker, C. G., & Arora, P. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101027118 · Cited by 35
The RAS-Binding Domain of Human BRAF Protein Serine/Threonine Kinase Exhibits Allosteric Conformational Changes upon Binding HRAS
Aramini, J. M., Vorobiev, S. M., Tuberty, L., Janjua, H., Campbell, E., Seetharaman, J., Su, M., Huang, Y. J., Acton, T., Xiao, R., et al. (2015) · Structure · doi:10.1016/j.str.2015.06.003 · Cited by 33
RasIns: Genetically Encoded Intrabodies of Activated Ras Proteins
Çetin, M. S., Evenson, W. E., Gross, G. G., Jalali‐Yazdi, F., Krieger, D., Arnold, D. B., Takahashi, T. T., & Roberts, R. W. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.008 · Cited by 32
Targeting the α4-α5 interface of RAS results in multiple levels of inhibition
Spencer-Smith, R., Li, L., Prasad, S., Koide, A., Koide, S., & O’Bryan, J. P. (2017) · Small GTPases · doi:10.1080/21541248.2017.1333188 · Cited by 32
Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells
Sheffels, E., Sealover, N. E., Theard, P. L., & Kortum, R. L. (2019) · Small GTPases · doi:10.1080/21541248.2019.1611168 · Cited by 31
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-07967-6 · Cited by 31
Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
Zubaidi, T. A., Gehrisch, O. H. F., Genois, M., Liu, Q., Lü, S., Kung, J., Xie, Y., Schuemann, J., Lu, H., Hata, A. N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83142-y · Cited by 34
Exploring KRas Protein Dynamics: An Integrated Molecular Dynamics Analysis of KRas Wild and Mutant Variants
Mir, S. A., Nayak, B., Aljarba, N. H., Kumarasamy, V., Subramaniyan, V., & Dhara, B. (2024) · ACS Omega · doi:10.1021/acsomega.4c02671 · Cited by 31
Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53 -Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas
He, F., Melamed, J., Tang, M., Huang, C., & Wu, X. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3067 · Cited by 31
Novel synthetic chalcones induce apoptosis in the A549 non-small cell lung cancer cells harboring a KRAS mutation
Wang, Y., Hedblom, A., Koerner, S. K., Li, M., Jernigan, F. E., Wegiel, B., & Sun, L. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.063 · Cited by 31
Phosphorylation of the C-Raf N Region Promotes Raf Dimerization
Takahashi, M., Li, Y., Dillon, T. J., Kariya, Y., & Stork, P. A. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00132-17 · Cited by 27
Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells
Trinidad, A. G., Whalley, N., Rowlinson, R. A., Delpuech, O., Dudley, P., Rooney, C., & Critchlow, S. E. (2017) · Oncogene · doi:10.1038/onc.2017.224 · Cited by 31
WDR76 degrades RAS and suppresses cancer stem cell activation in colorectal cancer
Ro, E. J., Cho, Y., Jeong, W.-J., Park, J., Min, D. S., & Choi, K. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0403-x · Cited by 31
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 33
Conformational Dynamics Allows Sampling of an “Active-like” State by Oncogenic K-Ras-GDP
Grudzien, P. K., Jang, H., Leschinsky, N., Nussinov, R., & Gaponenko, V. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167695 · Cited by 30
Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison
Chong, S. J. F., Lai, J. X. H., Eu, J. Q., Bellot, G. L., & Pervaiz, S. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7441 · Cited by 30
Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
Chiramel, J., Backen, A. C., Pihlak, R., Lamarca, Á., Frizziero, M., Tariq, N.-U.-A., Hubner, R. A., Valle, J. W., Amir, E., & McNamara, M. G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050909 · Cited by 30
Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders
D’Aria, F., D’Amore, V. M., Leva, F. S. D., Amato, J., Caterino, M., Russomanno, P., Salerno, S., Barresi, E., Leo, M. D., Marini, A. M., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105337 · Cited by 31
Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer
Li, F., Ng, W., Luster, T. A., Hu, H., Sviderskiy, V. O., Dowling, C. M., Hollinshead, K. E. R., Zouitine, P., Zhang, H., Huang, Q., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3782 · Cited by 29
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 31
Free Energy Profiles Relating With Conformational Transition of the Switch Domains Induced by G12 Mutations in GTP-Bound KRAS
Chen, J., Zhang, S., Zeng, Q., Wang, W., Zhang, Q., & Liu, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.912518 · Cited by 30
Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling
Luo, G., Wang, B., Hou, Q., & Wu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01729 · Cited by 30
Capturing the primordial Kras mutation initiating urethane carcinogenesis
Li, S., MacAlpine, D. M., & Counter, C. M. (2020) · Nature Communications · doi:10.1038/s41467-020-15660-8 · Cited by 28
NADPH oxidase 1 is highly expressed in human large and small bowel cancers
Lu, J., Jiang, G., Wu, Y., Antony, S., Meitzler, J. L., Juhasz, A. N., Liu, H., Roy, K., Makhlouf, H. R., Chuaqui, R. F., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233208 · Cited by 30
Inhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 29
Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
Shetu, S. A., & Bandyopadhyay, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073706 · Cited by 31
The renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 30
A fine balancing act: A delicate kinase-phosphatase equilibrium that protects against chromosomal instability and cancer
Cordeiro, M. H., Smith, R. J., & Saurin, A. T. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.017 · Cited by 28
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia
Rocca, S., Carrà, G., Poggio, P., Morotti, A., & Brancaccio, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0774-4 · Cited by 28
From Ras to Rap and Back, a Journey of 35 YearsPreprint
Bos, J. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031468 · Cited by 31
Engineering artificial non-coding RNAs for targeted protein degradation
Cao, C., Li, A., Xu, C., Wu, B., Yao, L., & Liu, Y. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01719-w · Cited by 30
A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma
Nagler, A., Vredevoogd, D. W., Alon, M., Cheng, P. F., Trabish, S., Kalaora, S., Arafeh, R., Goldin, V., Levesque, M. P., Peeper, D. S., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12825 · Cited by 28
KRAS regulation by small non-coding RNAs and SNARE proteins
Che, Y., Siprashvili, Z., Kovalski, J. R., Jiang, T., Wozniak, G. G., Elcavage, L. E., & Khavari, P. A. (2019) · Nature Communications · doi:10.1038/s41467-019-13106-4 · Cited by 30
Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior
Goswami, D., Chen, D., Yang, Y., Gudla, P. R., Columbus, J., Worthy, K. M., Rigby, M., Wheeler, M., Mukhopadhyay, S., Powell, K., et al. (2020) · eLife · doi:10.7554/elife.47654 · Cited by 28
Self-citation
Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1
Han, Y., Yu, C.-C., Fine, S. A., Youssof, A. L., Yang, Y., Yan, J., Karg, D. C., Cheung, E. C., Friedman, R. A., Ying, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02040-9 · Cited by 28
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach
McFall, T. B., & Stites, E. C. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110096 · Cited by 30
KRASpromoter oligonucleotide with decoy activity dimerizes into a unique topology consisting of two G-quadruplex units
Podbevšek, P., & Plavec, J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1359 · Cited by 28
The role of the oncogenic Rab35 in cancer invasion, metastasis, and immune evasion, especially in leukemia
Villagómez, F. R., Contreras, O. M., Cerna-Cortés, J. F., & Patiño‐López, G. (2018) · Small GTPases · doi:10.1080/21541248.2018.1463895 · Cited by 29
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
Kitai, H., & Ebi, H. (2016) · Small GTPases · doi:10.1080/21541248.2016.1210369 · Cited by 28
Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling
Umstead, M., Xiong, J., Qi, Q., Du, Y., & Fu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.15049 · Cited by 28
Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer
Luangdilok, S., Wanchaijiraboon, P., Chantranuwatana, P., Teerapakpinyo, C., Shuangshoti, S., & Sriuranpong, V. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.01 · Cited by 28
Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets
Cooley, R., Kara, N., Hui, N. S., Tart, J., Roustan, C., George, R., Hancock, D. C., Binkowski, B. F., Wood, K. V., Ismail, M., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15675.1 · Cited by 25
Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety
Grant, B., Enomoto, M., Back, S.-I., Lee, K., Gebregiworgis, T., Ishiyama, N., Ikura, M., & Marshall, C. B. (2020) · Science Signaling · doi:10.1126/scisignal.aaz0344 · Cited by 27
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
Ward, A., Keeton, A. B., Chen, X., Mattox, T. E., Coley, A. B., Maxuitenko, Y. Y., Buchsbaum, D. J., Randall, T. D., Zhou, G., & Piazza, G. A. (2020) · MedComm · doi:10.1002/mco2.10 · Cited by 28
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis
Tabibzadeh, A., Tameshkel, F. S., Moradi, Y., Soltani, S., Moradi‐Lakeh, M., Ashrafi, G. H., Motamed, N., Zamani, F., Motevalian, S. A., Panahi, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73770-1 · Cited by 29
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 28
The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways
Cáceres-Gutiérrez, R. E., Alfaro‐Mora, Y., Andonegui, M. A., Díaz‐Chávez, J., & Herrera, L. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.751367 · Cited by 28
Cell-Free, Embryo-Specific sncRNA as a Molecular Biological Bridge between Patient Fertility and IVF Efficiency
Timofeeva, A. V., Chagovets, V., Drapkina, Y. S., Makarova, N. P., Kalinina, E. A., & Sukhikh, G. T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122912 · Cited by 28
Monitoring the Waiting Time Sequence of Single Ras GTPase Activation Events Using Liposome Functionalized Zero-Mode Waveguides
Christensen, S. M., Triplet, M. G., Rhodes, C., Iwig, J. S., Tu, H., Stamou, D. G., & Groves, J. T. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00969 · Cited by 25
Novel Targeted Therapies for Metastatic Melanoma
Iams, W. T., Sosman, J. A., & Chandra, S. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000242 · Cited by 28
Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin
Ni, D., Liu, D., Zhang, J., & Lu, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010151 · Cited by 26
INDRA-IPM: interactive pathway modeling using natural language with automated assembly
Todorov, P. V., Gyori, B. M., Bachman, J. A., & Sorger, P. K. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz289 · Cited by 26
KRAS signaling in malignant pleural mesothelioma
Marazioti, A., Krontira, A. C., Behrend, S. J., Giotopoulou, G. A., Ntaliarda, G., Blanquart, C., Bayram, H., Iliopoulou, M. P., Vreka, M., Trassl, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013631 · Cited by 27
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
Entrialgo‐Cadierno, R., Cueto‐Ureña, C., Welch, C., Feliu, I., Macaya, I., Vera, L., Morales, X., Michelina, S. V., Scaparone, P., López, I., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01788-w · Cited by 25
Uncovering metabolism in rhabdomyosarcoma
Monti, E., & Fanzani, A. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1071746 · Cited by 26
Stapled Peptides: Providing the Best of Both Worlds in Drug Development
Xie, X., Gao, L., Shull, A. Y., & Teng, Y. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0102 · Cited by 27
Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes
Stephens, R. M., Yi, M., Kessing, B. D., Nissley, D. V., & McCormick, F. P. (2017) · Cancer Informatics · doi:10.1177/1176935117711944 · Cited by 26
Self-citation
Inhibition of Ral GTPases Using a Stapled Peptide Approach
Thomas, J. C., Cooper, J. M., Clayton, N. S., Wang, C., White, M. A., Abell, C., Owen, D., & Mott, H. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.720243 · Cited by 25
Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors
McFall, T. B., Schomburg, N. K., Rossman, K. L., & Stites, E. C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00645-3 · Cited by 26
A functional genomic approach to actionable gene fusions for precision oncology
Li, J., Lu, H., Ng, P. K., Pantazi, A., Ip, C. K. M., Jeong, K. J., Amador, B. E., Tran, R., Tsang, Y. H., Yang, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm2382 · Cited by 24
Optical tweezers for drug discovery
Halma, M. T. J., Tuszyński, J. A., & Wuite, G. J. L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103443 · Cited by 25
ATOH8 binds SMAD3 to induce cellular senescence and prevent Ras-driven malignant transformation
Liu, X., Li, X., Wang, S., Liu, Q., Feng, X., Wang, W., Huang, Z., Huang, Y., Wu, J., Cai, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208927120 · Cited by 27
MAPK signaling triggers transcriptional induction of cFOS during amino acid limitation of HepG2 cells
Shan, J., Donelan, W., Hayner, J. N., Zhang, F., Dudenhausen, E. E., & Kilberg, M. S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.12.013 · Cited by 25
Observing Extremely Weak Protein–Protein Interactions with Conventional Single-Molecule Fluorescence Microscopy
Yoo, J., Lee, T.-S., Choi, B., Shon, M. J., & Yoon, T. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09542 · Cited by 25
Common mechanisms of catalysis in small and heterotrimeric GTPases and their respective GAPs
Gerwert, K. B., Mann, D., & Kötting, C. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0314 · Cited by 25
Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers
Mattox, T. E., Chen, X., Maxuitenko, Y. Y., Keeton, A. B., & Piazza, G. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010141 · Cited by 25
A treatment strategy for KRAS-driven tumors
Mai, T. T., & Lito, P. (2018) · Nature Medicine · doi:10.1038/s41591-018-0111-x · Cited by 24
Inhibition of Ras Signaling by Blocking Ras–Effector Interactions with Cyclic Peptides
Upadhyaya, P., Qian, Z., Selner, N. G., Clippinger, S. R., Wu, Z., Briesewitz, R., & Pei, D. (2015) · Angewandte Chemie · doi:10.1002/ange.201502763 · Cited by 24
Ablation of insulin receptor substrates 1 and 2 suppresses Kras -driven lung tumorigenesis
Xu, H., Lee, M.-S., Tsai, P.-Y., Adler, A., Curry, N. L., Challa, S. P., Freinkman, E., Hitchcock, D. S., Copps, K. D., White, M. F., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718414115 · Cited by 24
Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway
Lai, H., Wang, Y., Duan, F., Li, Y., Jiang, Z., Luo, L., Liu, L., Leung, E. L., & Yao, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00958 · Cited by 24
C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event
Messenger, Z. J., Hall, J. R., Jima, D. D., House, J. S., Tam, H. W., Tokarz, D. A., & Smart, R. C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1103-y · Cited by 25
Activation of G Proteins by Guanine Nucleotide Exchange Factors Relies on GTPase Activity
Stanley, R. J., & Thomas, G. M. H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151861 · Cited by 24
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor
Ishida, N., Fukazawa, T., Maeda, Y., Yamatsuji, T., Kato, K., Matsumoto, K., Shimo, T., Takigawa, N., Whitsett, J. A., & Naomoto, Y. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.03.019 · Cited by 23
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 23
Targeting RAS in neuroblastoma: Is it possible?
Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24
Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants
Khan, I., Koide, A., Zuberi, M., Ketavarapu, G., Denbaum, E., Teng, K. W., Rhett, J. M., Spencer-Smith, R., Hobbs, G. A., Camp, E. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110322 · Cited by 24
Functional divergence caused by mutations in an energetic hotspot in ERK2
Taylor, C. A., Cormier, K. W., Keenan, S. E., Earnest, S. A., Stippec, S., Wichaidit, C., Juang, Y.-C. A., Wang, J., Shvartsman, S. Y., Goldsmith, E. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905015116 · Cited by 23
Mechanisms by Which Pleiotropic Amphiphilic n−3 PUFA Reduce Colon Cancer Risk
Chapkin, R. S., DeClercq, V., Kim, E., Fuentes, N. R., & Fan, Y. (2014) · Current Colorectal Cancer Reports · doi:10.1007/s11888-014-0241-6 · Cited by 24
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer
Cheng, H., & Planken, S. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00311 · Cited by 23
Cancer signaling: when phosphorylation meets methylation
Ying, H., & DePinho, R. A. (2014) · Cell Research · doi:10.1038/cr.2014.103 · Cited by 22
Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA
Papke, B., Azam, S. H., Feng, A. Y., Gutierrez-Ford, C., Huggins, H., Pallan, P. S., Van Swearingen, A. E. D., Egli, M., Cox, A. D., Der, C. J., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00165 · Cited by 22
Producing recombinant proteins in Vibrio natriegens
Smith, M. M., Hernández, J. S., Messing, S. A. J., Ramakrishnan, N., Higgins, B., Mehalko, J. L., Perkins, S. C., Wall, V. E., Grose, C., Frank, P. H., et al. (2024) · Microbial Cell Factories · doi:10.1186/s12934-024-02455-5 · Cited by 22
Self-citation
Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
Akkad, J., Bochum, S., & Martens, U. M. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1276-0 · Cited by 22
Structural characterization of 14-3-3ζ in complex with the human Son of sevenless homolog 1 (SOS1)
Ballone, A., Centorrino, F., Wolter, M., & Ottmann, C. (2018) · Journal of Structural Biology · doi:10.1016/j.jsb.2018.01.011 · Cited by 20
Osteopontin drives KRAS-mutant lung adenocarcinoma
Giopanou, I., Kanellakis, N. I., Giannou, A. D., Lilis, I., Marazioti, A., Σπέλλα, Μ., Papaleonidopoulos, V., Simoes, D. C. M., Zazara, D. E., Agalioti, T., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz190 · Cited by 22
Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints
Alexander, P., Chan, A. H., Rabara, D., Swain, M., Larsen, E. K., Dyba, M. D., Chertov, O., Ashraf, M., Champagne, A., Lin, K. Y., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110331 · Cited by 24
Self-citation

Authors: Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F.
Affiliations: Frederick National Laboratory for Cancer Research (US)
University of California, San Francisco (US)
Corresponding author: McCormick, Frank
ORCID: Stephen, Andrew G.
Esposito, Dominic
McCormick, Frank
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2014-03
Volume: 25
Issue: 3
Pages: 272-281
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2014.02.017
OpenAlex: W2022920832
Cited by: 795
References: 87
Citations by year: 2026: 25 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 59 · 2021: 63 · 2020: 67 · 2019: 84 · 2018: 95 · 2017: 94 · 2016: 82 · 2015: 80 · 2014: 31
FWCI: 8.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 404 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: Frederick National Laboratory for Cancer Research
National Institutes of Health
University of California, San Francisco
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords: Ras proteins, RAS-driven cancers, undruggable proteins, Ras signaling, Ras effectors, RAS inhibitors, cancer therapy
MeSH terms: Animals, Guanosine Diphosphate, Guanosine Triphosphate, Humans, Neoplasms, Protein Processing, Post-Translational, Retroviridae Infections, Tumor Virus Infections, Signal Transduction, Oncogene Protein p21(ras), Proto-Oncogene Proteins p21(ras), Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dragging Ras Back in the Ring

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks